Home | | | Search | | | Browse | | | Resources | | | Help | | | What's New | | | About |
---|
A 28-Day Study of Diclazuril in the Treatment of Cryptosporidiosis in Patients with AIDS
This study has been completed.
Sponsored by: | Janssen Pharmaceutica |
---|---|
Information provided by: | AIDS Clinical Trials Information Service |
Purpose
To evaluate the safety and efficacy of diclazuril capsules as a treatment for cryptosporidial related diarrhea in AIDS patients who have been treated in the double-blind study # JRD 64,433/1101 and have relapsed, or de-novo patients who have been diagnosed with cryptosporidial related diarrhea and who meet the inclusion and exclusion criteria of this protocol.
Condition | Treatment or Intervention |
---|---|
Cryptosporidiosis HIV Infections |
Drug: Diclazuril |
MedlinePlus related topics: AIDS; Cryptosporidiosis
Study Type: Interventional
Study Design: Treatment
Official Title: 28 Day Protocol for the Treatment of Cryptosporidiosis in AIDS Patients with Diclazuril (R64,433)
Eligibility
Ages Eligible for Study: 12 Years - 65 Years, Genders Eligible for Study: Both
Criteria
Inclusion Criteria
Concurrent Medication: Allowed:
Patients must have the following: Written informed consent given after the purpose and nature of the study, as well as the possible adverse effects related to the study drug, have been explained.
Prior Medication: Allowed:
Exclusion Criteria
Co-existing Condition: Patients with the following conditions or symptoms are excluded:
Concurrent Medication: Excluded:
Patients with the following are excluded:
Prior Medication: Excluded:
Location Information
More Information
U.S. National Library of Medicine, Contact NLM Customer Service | ||||||||||||||
National Institutes of Health, Department of Health & Human Services | ||||||||||||||
Copyright, Privacy, Accessibility, Freedom of Information Act |